First-in-Class Nasal Spray Could Both Treat and Prevent COVID-19
By HospiMedica International staff writers Posted on 17 Jun 2021 |
Image: First-in-Class Nasal Spray Could Both Treat and Prevent COVID-19 (Photo courtesy of ENA Respiratory)
A first-in-class nasal spray is being developed for the treatment as well as prevention of COVID-19 and other respiratory viral infections.
ENA Respiratory (Perth, Australia) is developing its lead clinical candidate, INNA-051, to activate innate immunity in the nose, the primary site of most respiratory virus infections, including COVID-19. The company is poised to initiate its Phase I human safety study of INNA-051 in the coming weeks.
Unlike other potential prophylactic approaches to COVID, INNA-051 directly stimulates the host’s innate immune defense that plays a key role in clearing viruses and other pathogens. A gold-standard animal study performed by Public Health England (PHE) demonstrated that ENA’s nasal spray reduces COVID-19 viral replication by up to 96%. If humans respond in a similar way, the spray could be used to protect people very quickly from infection and lower community transmission. Based on its mechanism of action and non-clinical studies demonstrating efficacy against multiple, non-related respiratory viruses, INNA-051 has the potential to prevent existing and emerging respiratory viral infections, such as COVID-19 and its variants.
The key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation, durable immune response supporting twice-weekly administration and compatibility with vaccine and intranasal corticosteroids.
“We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19,” said Chris Smith, Ph.D., Chairman of ENA Respiratory. “INNA-051 could be incredibly helpful in protecting at-risk populations such as health workers, the elderly and immunocompromised patients against existing and emerging variants. Because INNA-051 is not virus-specific, it could also play a key role beyond fighting the COVID-19 pandemic, in combating seasonal flu or any future respiratory viral outbreaks.”
Related Links:
ENA Respiratory
ENA Respiratory (Perth, Australia) is developing its lead clinical candidate, INNA-051, to activate innate immunity in the nose, the primary site of most respiratory virus infections, including COVID-19. The company is poised to initiate its Phase I human safety study of INNA-051 in the coming weeks.
Unlike other potential prophylactic approaches to COVID, INNA-051 directly stimulates the host’s innate immune defense that plays a key role in clearing viruses and other pathogens. A gold-standard animal study performed by Public Health England (PHE) demonstrated that ENA’s nasal spray reduces COVID-19 viral replication by up to 96%. If humans respond in a similar way, the spray could be used to protect people very quickly from infection and lower community transmission. Based on its mechanism of action and non-clinical studies demonstrating efficacy against multiple, non-related respiratory viruses, INNA-051 has the potential to prevent existing and emerging respiratory viral infections, such as COVID-19 and its variants.
The key features of INNA-051 intranasal administration include limited minimal or no systemic bioavailability, minimal or no systemic pro-inflammatory cytokine release, no direct type I interferon upregulation, durable immune response supporting twice-weekly administration and compatibility with vaccine and intranasal corticosteroids.
“We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19,” said Chris Smith, Ph.D., Chairman of ENA Respiratory. “INNA-051 could be incredibly helpful in protecting at-risk populations such as health workers, the elderly and immunocompromised patients against existing and emerging variants. Because INNA-051 is not virus-specific, it could also play a key role beyond fighting the COVID-19 pandemic, in combating seasonal flu or any future respiratory viral outbreaks.”
Related Links:
ENA Respiratory
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans